A Phase II Trial to Assess the Activity of NY-ES-O1 Targeted T Cells in Advanced Oesophagogastric Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs GSK 3377794 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ATTACK-OG; Y-ESO1OG
- 30 Jun 2019 Trial has been discontinued in UK, according to European Clinical Trials Database record.
- 07 Aug 2018 According to the ClinicalTrials.gov record, the study was terminated in United Kingdom due to Withdrawal of funding.
- 02 May 2018 Status changed from active, no longer recruiting to completed.